146 related articles for article (PubMed ID: 22139487)
1. [Gemcitabine plus S-1 combination therapy (GS therapy) for pancreatic cancer patients with high-grade hepatic metastasis].
Matsumoto T; Takeji S; Asagi A; Kajiwara T; Nishina T; Hori S; Ikeda Y; Nadano S; Iguchi H
Nihon Shokakibyo Gakkai Zasshi; 2011 Dec; 108(12):2003-9. PubMed ID: 22139487
[TBL] [Abstract][Full Text] [Related]
2. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Ueno H; Okusaka T; Furuse J; Yamao K; Funakoshi A; Boku N; Ohkawa S; Yokosuka O; Tanaka K; Moriyasu F; Nakamori S; Sato T
Jpn J Clin Oncol; 2011 Aug; 41(8):953-8. PubMed ID: 21715364
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
Ueno H; Okusaka T; Ikeda M; Ishiguro Y; Morizane C; Matsubara J; Furuse J; Ishii H; Nagase M; Nakachi K
Oncology; 2005; 69(5):421-7. PubMed ID: 16319514
[TBL] [Abstract][Full Text] [Related]
5. S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
Kim MK; Lee KH; Jang BI; Kim TN; Eun JR; Bae SH; Ryoo HM; Lee SA; Hyun MS
Jpn J Clin Oncol; 2009 Jan; 39(1):49-53. PubMed ID: 19060295
[TBL] [Abstract][Full Text] [Related]
6. Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer.
Suzuki S; Ozaki Y; Saida S; Kaji S; Koike N; Harada N; Hayashi T; Suzuki M
Hepatogastroenterology; 2013 Jun; 60(124):916-20. PubMed ID: 23478143
[TBL] [Abstract][Full Text] [Related]
7. [Two Cases of Liver Metastasis from Pancreatic Cancer with a Complete Response Owing to Chemotherapy].
Suda H; Omori K; Suematsu Y; Hiratsuka M; Takahashi M; Saito H; Ishibashi Y; Morita A; Wakabayashi K; Ito Y
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2388-90. PubMed ID: 26805373
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
Saito K; Isayama H; Nakai Y; Takahara N; Ishigaki K; Takeda T; Hakuta R; Saito T; Uchino R; Kishikawa T; Hamada T; Mizuno S; Sasaki T; Kogure H; Matsubara S; Yamamoto N; Ijichi H; Tateishi K; Tada M; Koike K
Invest New Drugs; 2019 Apr; 37(2):338-344. PubMed ID: 30411217
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.
Sudo K; Ishihara T; Hirata N; Ozawa F; Ohshima T; Azemoto R; Shimura K; Nihei T; Nishino T; Nakagawa A; Nakamura K; Hara T; Tada M; Mikata R; Tawada K; Yokosuka O; Nakaji S; Yamaguchi T
Cancer Chemother Pharmacol; 2014 Feb; 73(2):389-96. PubMed ID: 24322377
[TBL] [Abstract][Full Text] [Related]
10. [A case of pancreatic neuroendocrine tumor with excessively-advanced liver metastasis treated with S-1/GEM combination chemotherapy plus the long-acting somatostatin analogue octreotide].
Yoshida Y; Sugawara N; Minami T; Iwata N; Ikeda K; Endoh T; Sasano H
Nihon Shokakibyo Gakkai Zasshi; 2013 Apr; 110(4):660-8. PubMed ID: 23558130
[TBL] [Abstract][Full Text] [Related]
11. [A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by s-1 and gemcitabine combination chemotherapy].
Hoshino H; Takeda Y; Nagano H; Nakamori S; Kobayashi S; Eguchi H; Marubashi S; Tanemura M; Kitagawa T; Umeshita K; Monden M; Doki Y; Mori M
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2419-21. PubMed ID: 20037442
[TBL] [Abstract][Full Text] [Related]
12. A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer.
Nakai Y; Isayama H; Sasaki T; Sasahira N; Ito Y; Kogure H; Togawa O; Matsubara S; Arizumi T; Yagioka H; Yashima Y; Kawakubo K; Mizuno S; Yamamoto K; Hirano K; Tsujino T; Ijichi H; Toda N; Tada M; Kawabe T; Omata M
Oncology; 2009; 77(5):300-3. PubMed ID: 19923869
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
Ozaka M; Matsumura Y; Ishii H; Omuro Y; Itoi T; Mouri H; Hanada K; Kimura Y; Maetani I; Okabe Y; Tani M; Ikeda T; Hijioka S; Watanabe R; Ohoka S; Hirose Y; Suyama M; Egawa N; Sofuni A; Ikari T; Nakajima T
Cancer Chemother Pharmacol; 2012 May; 69(5):1197-204. PubMed ID: 22249272
[TBL] [Abstract][Full Text] [Related]
14. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.
Okusaka T; Miyakawa H; Fujii H; Nakamori S; Satoh T; Hamamoto Y; Ito T; Maguchi H; Matsumoto S; Ueno H; Ioka T; Boku N; Egawa S; Hatori T; Furuse J; Mizumoto K; Ohkawa S; Yamaguchi T; Yamao K; Funakoshi A; Chen JS; Cheng AL; Sato A; Ohashi Y; Tanaka M;
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1053-1059. PubMed ID: 28210843
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine plus S-1 for metastatic pancreatic cancer.
Zhu H; Yi C; Zhao Y; Gou H
Medicine (Baltimore); 2018 Oct; 97(41):e12836. PubMed ID: 30313120
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Kondo N; Nakagawa N; Sueda T
J Surg Oncol; 2012 Aug; 106(2):174-80. PubMed ID: 22331838
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.
Lee GW; Kim HJ; Ju JH; Kim SH; Kim HG; Kim TH; Kim HJ; Jeong CY; Kang JH
Cancer Chemother Pharmacol; 2009 Sep; 64(4):707-13. PubMed ID: 19151975
[TBL] [Abstract][Full Text] [Related]
19. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
[TBL] [Abstract][Full Text] [Related]
20. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
